CDKN2A and carcinoma of esophagus: Preclinical evidence supports that combining KRAS G12C inhibitors with CDK4/6 inhibitors could yield synergistic antitumor effects in NSCLC, colorectal, pancreatic, and oesophagal cancers, particularly when cell cycle control is compromised due to CDKN2A/B deletion or p16 inactivation [53,54].